BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wallings RL, Herrick MK, Tansey MG. LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's. Front Neurosci 2020;14:443. [PMID: 32508566 DOI: 10.3389/fnins.2020.00443] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Filippone A, Mannino D, Cucinotta L, Paterniti I, Esposito E, Campolo M. LRRK2 Inhibition by PF06447475 Antagonist Modulates Early Neuronal Damage after Spinal Cord Trauma. Antioxidants 2022;11:1634. [DOI: 10.3390/antiox11091634] [Reference Citation Analysis]
2 Thakur G, Kumar V, Lee KW, Won C. Structural Insights and Development of LRRK2 Inhibitors for Parkinson’s Disease in the Last Decade. Genes 2022;13:1426. [DOI: 10.3390/genes13081426] [Reference Citation Analysis]
3 Wallings RL, Hughes LP, Staley HA, Simon ZD, McFarland NR, Alcalay RN, Garrido A, Martí MJ, Sarró ET, Dzamko N, Tansey MG. WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes. Front Cell Neurosci 2022;16:892899. [PMID: 35755775 DOI: 10.3389/fncel.2022.892899] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Terkelsen MH, Klaestrup IH, Hvingelby V, Lauritsen J, Pavese N, Romero-Ramos M. Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies. J Parkinsons Dis 2022. [PMID: 35723115 DOI: 10.3233/JPD-223245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Russo I, Bubacco L, Greggio E. LRRK2 as a target for modulating immune system responses. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105724] [Reference Citation Analysis]
6 Ahmadi Rastegar D, Hughes LP, Perera G, Keshiya S, Zhong S, Gao J, Halliday GM, Schüle B, Dzamko N. Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinsons Dis 2022;8:34. [PMID: 35347144 DOI: 10.1038/s41531-022-00297-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kasen A, Houck C, Burmeister AR, Sha Q, Brundin L, Brundin P. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Lara Ordóñez AJ, Fasiczka R, Naaldijk Y, Hilfiker S. Rab GTPases in Parkinson's disease: a primer. Essays Biochem 2021;65:961-74. [PMID: 34414419 DOI: 10.1042/EBC20210016] [Reference Citation Analysis]
9 Yu E, Ambati A, Andersen MS, Krohn L, Estiar MA, Saini P, Senkevich K, Sosero YL, Sreelatha AAK, Ruskey JA, Asayesh F, Spiegelman D, Toft M, Viken MK, Sharma M, Blauwendraat C, Pihlstrøm L, Mignot E, Gan-Or Z. Fine mapping of the HLA locus in Parkinson's disease in Europeans. NPJ Parkinsons Dis 2021;7:84. [PMID: 34548497 DOI: 10.1038/s41531-021-00231-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Wojewska DN, Kortholt A. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease. Biomolecules 2021;11:1101. [PMID: 34439767 DOI: 10.3390/biom11081101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang X, Negrou E, Maloney MT, Bondar VV, Andrews SV, Montalban M, Llapashtica C, Maciuca R, Nguyen H, Solanoy H, Arguello A, Przybyla L, Moerke NJ, Huntwork-Rodriguez S, Henry AG. Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10. Sci Rep 2021;11:12900. [PMID: 34145320 DOI: 10.1038/s41598-021-91943-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Unda SR, Antoniazzi AM, Altschul DJ, Marongiu R. Peripheral Leukocytosis Predicts Cognitive Decline but Not Behavioral Disturbances: A Nationwide Study of Alzheimer's and Parkinson's Disease Patients. Dement Geriatr Cogn Disord 2021;50:143-52. [PMID: 34058741 DOI: 10.1159/000516340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Thome AD, Atassi F, Wang J, Faridar A, Zhao W, Thonhoff JR, Beers DR, Lai EC, Appel SH. Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease. NPJ Parkinsons Dis 2021;7:41. [PMID: 33986285 DOI: 10.1038/s41531-021-00188-5] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
14 Usmani A, Shavarebi F, Hiniker A. The Cell Biology of LRRK2 in Parkinson's Disease. Mol Cell Biol 2021;41:e00660-20. [PMID: 33526455 DOI: 10.1128/MCB.00660-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Herrick MK, Tansey MG. Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease? NPJ Parkinsons Dis 2021;7:26. [PMID: 33750819 DOI: 10.1038/s41531-021-00170-1] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
16 Pischedda F, Piccoli G. LRRK2 at the pre-synaptic site: A 16-years perspective. J Neurochem 2021;157:297-311. [PMID: 33206398 DOI: 10.1111/jnc.15240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chittoor-Vinod VG, Nichols RJ, Schüle B. Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism. Int J Mol Sci 2021;22:1045. [PMID: 33494262 DOI: 10.3390/ijms22031045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
18 Forloni G, La Vitola P, Cerovic M, Balducci C. Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. Prog Mol Biol Transl Sci 2021;177:175-202. [PMID: 33453941 DOI: 10.1016/bs.pmbts.2020.11.001] [Reference Citation Analysis]
19 Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. Mov Disord 2021;36:25-36. [PMID: 33314312 DOI: 10.1002/mds.28411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
20 Tan JSY, Chao YX, Rötzschke O, Tan EK. New Insights into Immune-Mediated Mechanisms in Parkinson's Disease. Int J Mol Sci 2020;21:E9302. [PMID: 33291304 DOI: 10.3390/ijms21239302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Pajares M, I Rojo A, Manda G, Boscá L, Cuadrado A. Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications. Cells 2020;9:E1687. [PMID: 32674367 DOI: 10.3390/cells9071687] [Cited by in Crossref: 121] [Cited by in F6Publishing: 88] [Article Influence: 60.5] [Reference Citation Analysis]